Skip to content
OpenCapital
Get started

Cytokinetics CYTK Q4 2025 Annual earnings

Reported February 24, 2026 · After market close

Revenue$17.8MBeat by $10.8MDiluted EPS-$1.50Miss by $0.02
Revenue estimate$6.9M
EPS estimate-$1.48

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$17.1M
EPS estimate-$1.64

Financials

Q4 2025

Income statement

See full
Revenue$17.8M+4.9%
Operating income-$178.4M-28.3%
Net income-$183.0M-22.0%
EPS (diluted)-$1.50-19.0%

Balance sheet

See full
Cash & equivalents$122.5M+29.2%
Total debt$414.6M+75.3%
Total equity-$659.6M-387%
Total assets$1.4B+1.6%

Cash flow

See full
Operating cash flow-$142.7M-118%
CapEx$5.6M+338%
Free cash flow-$148.3M-122%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$7.77B+39.9%
Enterprise value$8.06B+41.6%
P/S88.2×-212×

Profitability

See full
Operating margin-695.4%-300pp
Net margin-891.6%-373pp
FCF margin-607.5%-254pp

Returns & leverage

See full
Current ratio4.5×-1.6×

Segments

By product

See full
License And Milestone Revenues$15.0M0.0%
Collaboration Revenues$2.8M+43.0%

Versus estimates

Revenue

Q1 2026$19.4MBeat by $10.8M
Q4 2025$17.8MBeat by $10.8M
Q3 2025$1.9MMiss by $6.1MQ2 2025$66.8MBeat by $64.7MQ1 2025$1.6MMiss by $1.2MQ4 2024$16.9MBeat by $2.7M

Diluted EPS

Q1 2026-$1.67In line
Q4 2025-$1.50Miss by $0.02
Q3 2025-$1.54Beat by $0.05Q2 2025-$1.12Beat by $0.22Q1 2025-$1.36Beat by $0.05Q4 2024-$1.26Beat by $0.03

Ask the moment Cytokinetics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cytokinetics report Q4 2025 earnings?
Cytokinetics (CYTK) reported Q4 2025 earnings on February 24, 2026 after market close.
What were Cytokinetics's Q4 2025 revenue and EPS?
Cytokinetics reported revenue of $17.8M and diluted EPS of $-1.50 for Q4 2025.
Did Cytokinetics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $6.9M by $10.8M. EPS missed the consensus estimate of $-1.48 by $0.02.
How did Cytokinetics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4.9% from $16.9M a year earlier and diluted EPS declined 19.0% from $-1.26.
Where can I find Cytokinetics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-067012) and the 10-K periodic report (0001193125-26-076495) directly on SEC EDGAR. The filing index links above go to sec.gov.